Is sustained pain freedom and no adverse events a clinically relevant endpoint in acute migraine treatment?

Peer Tfelt-Hansen

doi:10.1177/0333102411398154

Is sustained pain freedom and no adverse events a clinically relevant endpoint in acute migraine treatment?

Originalsprog	Engelsk
Tidsskrift	Cephalalgia
Vol/bind	31
Udgave nummer	11
Sider (fra-til)	1240
ISSN	0333-1024
DOI	https://doi.org/10.1177/0333102411398154
Status	Udgivet - 2011

Adgang til dokumentet

10.1177/0333102411398154

Citationsformater

@article{6f8d1ed831804d7db93a6105b45dc791,

title = "Is sustained pain freedom and no adverse events a clinically relevant endpoint in acute migraine treatment?",

keywords = "Analgesics, Azepines, Female, Humans, Imidazoles, Male, Migraine Disorders, Oxazolidinones, Receptors, Calcitonin Gene-Related Peptide, Research Design, Tryptamines",

author = "Peer Tfelt-Hansen",

year = "2011",

doi = "10.1177/0333102411398154",

language = "English",

volume = "31",

pages = "1240",

journal = "Cephalalgia",

issn = "0333-1024",